Search PubMed⌕ Search

Biomedical subjects

H Duchková

Publications and source records attributed to H Duchková.

At least 19 recordsLinked to original sources
PubMed2006

[Contemporary alternatives in the diagnostics and therapy of female androgenetic alopecia].

Female androgenetic alopecia belongs to the family of scar-less, diffuse, telogenic, hormonally determined alopecias with hereditary disposition. In the androgenetic alopecia, progressive, androgen mediated miniaturization of genetically predestined hair follicles develops. Genetic factors play a role namely in females without the higher serum androgen level. Pathologically high level of serum androgens is usually accompanied with signs of virilization. Hair dropping starts in the fourth decade or earlier. It occurs in the postmenopausal period, after a pregnancy, after the onset or termination of peroral contraception, in women treated by aromatase inhibitors.

Alopecia↗
PubMed1998

[Immunomodulation in the treatment of atopic dermatitis].

In the submitted review the authors present information on possibilities of immunomodulating treatment of atopic dermatitis. Immunosuppressive treatment comprises systemic corticosteroid administration (possibly combined with cytostatic immunosuppressive preparations), cyclosporin A and phototherapy. Immunopotentiating treatment of AD makes use mainly of modulating preparations with the nature of physiological substances close to the immune system, substances obtained from natural biological sources (thymic hormones) or in recent years more frequently substances of recombinant origin (interferons, interleukins). The use of immunopotentiating drugs of chemical origin (synthetic substances) is used less frequently in AD. The use of intravenous immunoglobulin preparations for severe forms of atopic dermatitis is only just starting.

Adjuvants, Immunologic↗
PubMed1980

Urinary excretion of zinc and magnesium in malignant melanoma.

As zinc is the dominant trace element of melanin pigmentation, its urinary excretion was studied in 63 patients with malignant melanoma and also in groups of carcinoma patients and normal subjects. For comparison, magnesium excretion was also measured. As the melanoma progressed, the zinc excretion increased, but there was no correlation between the magnesium excretion and the stage of melanoma. There were no significant differences in excretion of either metal between the groups of treated melanoma patients, normal individuals, or the carcinoma patients.

Carcinoma↗